ACA-PSC Platform

About Aca Cell Biotech

Aca Cell Biotech is a private, pre-revenue biotech developing a novel platform for generating autologous, pluripotent stem cells from a patient's own peripheral blood. Its core technology centers on activating the GPI-linked ACA protein with a specific antibody to induce de-differentiation of blood progenitor cells into therapeutic stem cells, claiming advantages such as no tumor risk, no need for immunosuppression, and in situ differentiation. The company is at a pre-clinical R&D stage, aiming to create cellular therapies for conditions likely involving neurological and other degenerative diseases.

Therapeutic Areas